Novel pharmacotherapies for cardiac amyloidosis

Pharmacology and Therapeutics

Volumn 180, Issue , 2017, Pages 129-138

  Alexander, Kevin M ^a   Singh, Avinainder ^a   Falk, Rodney H ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Amyloidosis; Cardiomyopathy; Light chain; Neuropathy; Therapy; Transthyretin

Indexed keywords

AG 10; AMYLOID; AMYLOID P COMPONENT; ANTISENSE OLIGONUCLEOTIDE; BORTEZOMIB; CURCUMIN; DIFLUNISAL; DOXYCYCLINE; IMMUNOMODULATING AGENT; MELPHALAN; MONOCLONAL ANTIBODY; NEOD 001; PROTEASOME INHIBITOR; RNA; SINECATECHINS; STABILIZING AGENT; TAFAMIDIS; TAUROURSODEOXYCHOLIC ACID; TOLCAPONE; UNCLASSIFIED DRUG; ANTIBODY; PREALBUMIN;

AL AMYLOIDOSIS; ATTR AMYLOIDOSIS; CELL THERAPY; HEART AMYLOIDOSIS; PLASMA CELL; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; AMYLOIDOSIS; ANIMAL; HEART DISEASE; HUMAN; IMMUNOLOGY; METABOLISM;

AMYLOID; AMYLOIDOSIS; ANIMALS; ANTIBODIES; HEART DISEASES; HUMANS; PLASMA CELLS; PREALBUMIN;

EID: 85024089048     PISSN: 01637258     EISSN: 1879016X     Source Type: Journal    
DOI: 10.1016/j.pharmthera.2017.06.011     Document Type: Review

References (70)

1. Ackermann, E.J., Guo, S., Booten, S., Alvarado, L., Benson, M., Hughes, S., et al. Clinical development of an antisense therapy for the treatment of transthyretin-associated polyneuropathy. Amyloid 19 (2012), 43–44.
2. Adamski-Werner, S.L., Palaninathan, S.K., Scchettini, J.C., Kelly, J.W., Diflunisal analogues stabilize the native state of transthyretin. Potent inhibition of amyloidogenesis. Journal of Medicinal Chemistry 47 (2004), 355–374.
3. Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K.N., et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Molecular Therapy 18 (2010), 1357–1364.
4. Alhamadsheh, M.M., Connelly, S., Cho, A., Reixach, N., Powers, E.T., Pan, D.W., et al. Potent kinetic stabilizers that prevent transthyretin-mediated cardiomyocyte proteotoxicity. Science Translational Medicine, 3, 2011, 97ra81.
5. Aus dem Siepen, F., Buss, S.J., Andre, F., Seitz, S., Giannitsis, E., Steen, H., Katus, H.A., et al. Extracellular remodeling in patients with wild-type amyloidosis consuming epigallocatechin-3-gallate: Preliminary results of T1 mapping by cardiac magnetic resonance imaging in a small single center study. Clinical Research in Cardiology 104 (2015), 640–647.
6. Benson, M.D., Kluve-Beckerman, B., Zeldenrust, S.R., Siesky, A.M., Bodenmiller, D.M., Showalter, A.D., et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides. Muscle & Nerve 33 (2006), 609–618.
7. Berk, J.L., Suhr, O.B., Obici, L., Sekijima, Y., Zeldenrust, S.R., Yamashita, T., et al. Repurposing diflunisal for familial amyloid polyneuropathy: A randomized clinical trial. JAMA 310 (2013), 2658–2667.
8. Bodin, K., Ellmerich, S., Kahan, M.C., Tennent, G.A., Loesch, A., Gilbertson, J.A., et al. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits. Nature 468 (2010), 93–97.
9. Bulawa, C.E., Connelly, S., Devit, M., Wang, L., Weigel, C., Fleming, J.A., et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proceedings of the National Academy of Sciences of the United States of America 109 (2012), 9629–9634.
10. Cardoso, I., Martins, D., Ribeiro, T., Merlini, G., Saraiva, M.J., Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: Studies in FAP mouse models. Journal of Translational Medicine, 8, 2010, 74.
11. Cardoso, I., Merlini, G., Saraiva, M.J., 4′-Iodo-4′-deoxydoxorubicin and tetracyclines disrupts transthyretin amyloid fibrils in vitro producing noncytotoxic: Screening for TTR fibril disrupters. The FASEB Journal 17 (2003), 803–809.
12. Cardoso, I., Saraiva, M.J., Doxycycline disrupts transthyretin amyloid: Evidence from studies in a FAP transgenic mice model. The FASEB Journal 20 (2006), 234–239.
13. Castaño, A., Helmke, S., Alvarez, J., Delisle, S., Maurer, M.S., Diflunisal for ATTR cardiac amyloidosis. Congestive Heart Failure 18 (2012), 315–319.
14. Coelho, T., Adams, D., Silva, A., Lozeron, P., Hawkins, P.N., Mant, T., et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. The New England Journal of Medicine 369 (2013), 819–829.
15. Coelho, T., Maia, L.F., da Silva, A.M., Cruz, M.W., Planté-Bordenueve, V., Suhr, O.B., et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. Neurology 260 (2013), 2802–2814.
16. Coelho, T., Maia, L.F., Martins da Silva, A., Waddington Cruz, M., Planté-Bordenueve, V., Lozeron, P., et al. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology 79 (2012), 785–792.
17. Cohen, A.D., Landau, H., Scott, E.C., Liedtke, M., Kaufman, J.L., Rosenzweig, M., et al. Safety and efficacy of carfilzomib (CFZ) in previously-treated systemic light-chain (AL) amyloidosis. American Society of Hematology 58th annual meeting & exposition. December 5, 2016, 2016.
18. Conejos-Sánchez, I., Cardoso, I., Oteo-Vives, M., Romero-Sanz, E., Paul, A., Sauri, A.R., et al. Polymer-doxycycline conjugates as fibril disrupters: An approach towards the treatment of a rare amyloidotic disease. Journal of Controlled Release 198 (2015), 80–90.
19. Dietrich, S., Schönland, S.O., Benner, A., Bochtler, T., Kristen, A.V., Beimler, J., et al. Treatment with intravenous melphalan and dexamethasone is not able to overcome the poor prognosis of patients with newly diagnosed systemic light chain amyloidosis and severe cardiac involvement. Blood 116 (2010), 522–528.
20. Dispenzieri, A., Buadi, F., Kumar, S.K., Reeder, C.B., Sher, T., Lacy, M.Q., et al. Treatment of immunoglobulin light chain amyloidosis: Mayo stratification of myeloma and risk-adapted therapy (mSMART) consensus statement. Mayo Clinic Proceedings 90 (2015), 1054–1081.
21. Dispenzieri, A., Buadi, F., Laumann, K., Laplant, B., Hayman, S.R., Kumar, S.K., et al. Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis. Blood 119 (2012), 5397–5404.
22. Dubrey, S.W., Hawkins, P.N., Falk, R.H., Amyloid diseases of the heart: Assessment, diagnosis, and referral. Heart 97 (2011), 75–84.
23. Falk, R.H., Alexander, K.M., Liao, R., Dorbala, S., AL (light-chain) cardiac amyloidosis: A review of diagnosis and therapy. Journal of the American College of Cardiology 68 (2016), 1323–1341.
24. Ferreira, N., Goncalves, N.P., Saraiva, M.J., Almeida, M.R., Curcumin: A multi-target disease-modifying agent for late-stage transthyretin amyloidosis. Scientific Reports, 6, 2016, 26623 (Food and Drug Administration. May 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020697s004lbl.pdf). Accessed March 1, 2017).
25. Food and Drug Administration Center for Drug Evaluation and Research, Peripheral and central nervous system drugs advisory committee: Vyndaqel (tafamidis meglumine). http://www.fda.gov/downloads/AdvisorycommitteesMeetingMaterials/Drugs/PeripheralandCentralNervousSystemDrugsAdvisoryCommittee/UCM304830.pdf, 2012, May 24 (Accessed March 1, 2017).
26. Gertz, M.A., How to manage primary amyloidosis. Leukemia 26 (2012), 191–198.
27. Gertz, M.A., Landau, H., Comenzo, R.L., Seldin, D., Weiss, B., Zonder, J., et al. First-in-human phase I/II study of NEOD001 in patients with light chain amyloidosis and persistent organ dysfunction. Journal of Clinical Oncology 34 (2016), 1097–1103.
28. Gillimore, J.D., Tennent, G.A., Hutchinson, W.L., Gallimore, J.R., Lachmann, H.J., Goodman, H.J., et al. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis. British Journal of Haematology 148 (2010), 760–767.
29. Gislason, G.H., Rasmussen, J.N., Abildstrom, S.Z., Schramm, T.K., Hansen, M.L., Fosbøl, E.L., et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Archives of Internal Medicine, 169, 2009, 141.
30. Gooch, K., Culleton, B.F., Manns, B.J., Zhang, J., Alfonso, H., Tonelli, M., et al. NSAID use and progression of chronic kidney disease. The American Journal of Medicine 120 (2007), 280.e1–280.e7.
31. Hora, M., Carballo-Pacheco, M., Weber, B., Morris, V.K., Wittkopf, A., Buchner, J., Reif, B., Epigallocatechin-3-gallate preferentially induces aggregation of amyloidogenic immunoglobulin light chains. Scientific Reports, 7, 2017, 41515.
32. Jaccard, A., Moreau, P., Leblond, V., Leleu, X., Benboubker, L., Hermine, O., et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. The New England Journal of Medicine 357 (2007), 1083–1093.
33. Jones, N.F., Hilton, P.J., Tighe, J.R., Hobbs, J.R., Treatment of “primary” renal amyloidosis with melphalan. Lancet 2 (1972), 616–619.
34. Kastritis, E., Wechalekar, A.D., Dimopoulos, M.A., Merlini, G., Hawkins, P.N., Perfetti, V., et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. Journal of Clinical Oncology 28 (2010), 1031–1037.
35. Kaufman, G.P., Schrier, S.L., Lafayette, R.A., Arai, S., Witteles, R.M., Liedtke, M., Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood, 2017, Jun 14.
36. Kumar, S., Dispenzieri, A., Lacy, M.Q., Hayman, S.R., Buadi, F.K., Colby, C., et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. Journal of Clinical Oncology 30 (2012), 989–995.
37. Kumar, S.K., Hayman, S.R., Buadi, F.K., Roy, V., Lacy, M.Q., Gertz, M.A., et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: Long-term results from a phase 2 trial. Blood 119 (2012), 4860–4867.
38. Kyle, R.A., Greipp, P.R., O'Fallon, W.M., Primary systemic amyloidosis: Multivariate analysis for prognostic factors in 168 cases. Blood 68 (1986), 220–224.
39. Lozeron, P., Théaudin, M., Mincheva, Z., Ducot, B., Lacroix, C., Adams, D., et al. Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathy. European Journal of Neurology 20 (2013), 1539–1545.
40. Mahmood, S., Venner, C.P., Sachchithanantham, S., Lane, T., Rannigan, L., Foard, D., et al. Lenalidomide and dexamethasone for systemic AL amyloidosis following prior treatment with thalidomide or bortezomib regimens. British Journal of Haematology 166 (2014), 842–848.
41. Maurer, M.S., Grogan, D.R., Judge, D.P., Mundayat, R., Packman, J., Lombardo, I., et al. Tafamidis in transthyretin amyloid cardiomyopathy: Effects on transthyretin stabilization and clinical outcomes. Circulation. Heart Failure 8 (2015), 519–526.
42. Mereles, D., Buss, S.J., Hardt, S.E., Hunstein, W., Katus, H.A., Effects of the main green tea polyphenol epigallocatechin-3-gallate on cardiac involvement in patients with AL amyloidosis. Clinical Research in Cardiology 99 (2010), 483–490.
43. Mikhael, J., Management of carfilzomib-associated cardiac adverse events. Clinical Lymphoma, Myeloma & Leukemia 16 (2016), 241–245.
44. Mikhael, J.R., Schuster, S.R., Jimenez-Zepeda, V.H., Bello, N., Spong, J., Reeder, C.B., et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 19 (2012), 4391–4394.
45. Miller, S.R., Sekijima, Y., Kelly, J.W., Native state stabilization by NSAIDs inhibits transthyretin amyloidogenesis from the most common familial disease variants. Laboratory Investigation 84 (2004), 545–552.
46. Obici, L., Cortese, A., Lozza, A., Lucchetti, J., Gobbi, M., Palladini, G., et al. Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: A phase II study. Amyloid 19 (2012), 34–36.
47. Oliva, L., Orfanelli, U., Resnati, M., Raimondi, A., Orsi, A., Milan, E., et al. The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity. Blood 129:15 (2017, Apr 13), 2132–2142.
48. Palladini, G., Milani, P., Foli, A., Obici, L., Lavatelli, F., Nuvolone, M., et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: Long-term results of a risk-adapted approach. Haematologica 99 (2014), 743–750.
49. Palladini, G., Perfetti, V., Obici, L., Caccialanza, R., Semino, A., Adami, F., et al. Association of melphalan and high-dose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 103 (2004), 2936–2938.
50. Palladini, G., Sachchithanantham, S., Milani, P., Gillmore, J., Foli, A., Lachmann, H., et al. A European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis. Blood 126 (2015), 612–615.
51. Penchala, S.C., Connelly, S., Wang, Y., Park, M.S., Zhao, L., Baranczak, A., et al. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proceedings of the National Academy of Sciences of the United States of America 110 (2013), 9992–9997.
52. Pepys, M.B., Hebert, J., Hutchinson, W.L., Tennent, G.A., Lachmann, H.J., Gallimore, J.R., et al. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417 (2002), 254–259.
53. Pullakhandam, R., Srinivas, P.N., Nair, M.K., Reddy, G.B., Binding and stabilization of transthyretin by curcumin. Archives of Biochemistry and Biophysics 485 (2009), 115–119.
54. Quarta, C.C., Buxbaum, J.N., Shah, A.M., Falk, R.H., Claggett, B., Kitzman, D.W., et al. The amyloidogenic V122I transthyretin variant in elderly black Americans. The New England Journal of Medicine 372 (2015), 21–29.
55. Razavi, H., Palaninathan, S.K., Powers, E.T., Wiseman, R.L., Purkey, H.E., Mohamedmohaideen, N.N., et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: Synthesis, evaluation, and mechanism of action. Angewandte Chemie (International Ed. in English) 42 (2003), 2758–2761.
56. Richards, D.B., Cookson, L.M., Berges, A.C., Barton, S.V., Lane, T., Ritter, J.M., et al. Therapeutic clearance of amyloid by antibodies to serum amyloid P component. The New England Journal of Medicine 373 (2015), 1106–1114.
57. Ruberg, F.L., Maurer, S.M., Judge, D.P., Zeldenrust, S., Skinner, M., Kim, A.Y., et al. Prospective evaluation of the morbidity and mortality of wild-type and V122I mutant transthyretin amyloid cardiomyopathy: The Transthyretin Amyloidosis Cardiac Study (TRACS). American Heart Journal 164 (2012), 222–228.
58. Sanchorawala, V., Palladini, G., Kukreti, V., Zonder, J.A., Cohen, A.D., Seldin, D.C., et al. A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory light-chain (AL) amyloidosis. Blood, 2017, May 26, 10.1182/blood-2017-03-771220.
59. Sanchorawala, V., Shelton, A.C., Lo, S., Varga, C., Sloan, J.M., Seldin, D.C., Pomalidomide and dexamethasone in the treatment of AL amyloidosis: Results of a phase 1 and 2 trial. Blood 128 (2016), 1059–1062.
60. Sant'Anna, R., Gallego, P., Robinson, L.Z., Pereira-Henriques, A., Ferreira, N., Pinheiro, F., et al. Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nature Communications, 7, 2016, 10787.
61. Scott, L.J., Tafamidis: A review of its use in familial amyloid polyneuropathy. Drugs 74 (2014), 1371–1378.
62. Sekijima, Y., Dendle, M.A., Kelly, J.W., Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 13 (2006), 236–249.
63. Sher, T., Fenton, B., Akhtar, A., Gertz, M.A., First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis. Blood 128 (2016), 1987–1999.
64. Sitia, R., Palladini, G., Merlini, G., Bortezomib in the treatment of AL amyloidosis: Targeted therapy?. Haematologica 92 (2007), 1302–1307.
65. Sperry, B.W., Ikram, A., Hachamovitch, R., Valent, J., Vranian, M.N., Phelan, D., et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. Journal of the American College of Cardiology 67 (2016), 2941–2948.
66. Suhr, O.B., Coelho, T., Buades, J., Pouget, J., Conceiao, I., Berk, J., et al. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: A phase II multidose study. Orphanet Journal of Rare Diseases, 10, 2015, 109.
67. Tojo, K., Sekijima, Y., Kelly, J.W., Ikeda, S., Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis. Neuroscience Research 56 (2006), 441–449.
68. Venner, C.P., Lane, T., Foard, D., Rannigan, L., Gibbs, S.D., Pinney, J.H., et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood 119 (2012), 4387–4390.
69. Wall, J.S., Kennel, S.J., Williams, A., Richey, T., Stuckey, A., Huang, Y., et al. AL amyloid imaging and therapy with a monoclonal antibody to a cryptic epitope on amyloid fibrils. PloS One, 7, 2012, e52686.
70. Zimmermann, T.S., Lee, A.C., Akinc, A., Bramlage, B., Bumcrot, D., Fedoruk, M.N., et al. RNAi-mediated gene silencing in non-human primates. Nature 441 (2006), 111–114.